NCT00740181终止2 期
A Phase II Study With Decitabine, Low Dose Cytarabine and G-CSF in High-risk Myelodysplastic Syndromes, Refractory Acute Myeloid Leukemia or Acute Myeloid Leukemia in Patients With Significant Co-morbidities.
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 9
- 试验地点
- 1
- 主要终点
- Response Rate
研究概览
简要总结
This study will determine the activity of decitabine, low dose cytarabine (ARA-C) and G-CSF for patients with myelodysplasia and leukemia.
详细描述
The primary objective of this study is to determine the feasibility and toxicity of decitabine, ARA-C and G-CSF for patients with myelodysplasia, refractory acute leukemia and poor performance status acute leukemia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All patients must have histological confirmation of disease prior to enrollment on study.
- •Patients with de novo AML who are not eligible for induction chemotherapy are eligible. Patients with refractory, relapsed AML are eligible.
- •Patients with AML evolving from prior MDS or secondary to prior chemotherapy are eligible provided they are not eligible for standard induction chemotherapy.
- •Patients with MDS and with blasts > 10% (RAEB-II) are eligible.
- •Patients with extramedullary relapse only (i.e., leukemia cutis or other extramedullary site) are eligible as long as disease can be monitored.
- •Patients who have relapsed after standard autologous and/or allogeneic bone marrow transplant are eligible as long as they meet all other eligibility criteria.
- •Patients must not have had any chemotherapy, except hydrea, or radiation for at least 4 weeks prior.
- •Patients must be > 18 years of age.
- •Patients with an active second malignancy other than non-melanoma skin cancers are not eligible.
- •Patients must have an expected life expectancy of > 12 weeks at the time of enrollment.
- •Patients with visceral, blood stream or nervous system opportunistic infection are eligible if the infection has been appropriately treated and controlled. Patients with fungal lung infections must have had treatment for at least one month and have proof of regression prior to enrollment. Patients may be on antimicrobials at the time of therapy.
- •Initial required laboratory values:
- •Total Bilirubin < 2 X upper limit of normal.
- •AST & ALT < 3 X upper limit of normal (if elevated liver enzymes thought likely due to Leukemic infiltrate discuss with the Principal Investigator and the BrUOG Central Office).
- •Creatinine < 2 mg/dl.
- •< 15,000 K/uI blast count-Hydroxyurea can be used to decrease count if more than 15,000 K/ul.
- •Patients must have an ECOG performance status of 0-
- •Patients must receive and sign a full informed consent.
- •Patients should not have co-existing medical illnesses which would limit survival < 12 weeks.
- •No known history of HIV.
- •The safety of decitabine in human pregnancy is unknown. Based on animal studies, decitabine may cause fetal harm when administered to a pregnant woman. Therefore, it is important that you do not become pregnant or father a child while receiving study medication and for 2 months afterwards because the drugs in this study may affect an unborn baby.
- •If you are a woman capable of becoming pregnant (not surgically sterile or post-menopausal), you must have a negative pregnancy test before beginning treatment.
- •If you do become pregnant, suspect you are pregnant, or if your partner becomes pregnant while you are on this study, you must notify your study doctor immediately. If you become pregnant, you will be taken off this study.
- •In addition, you must not breast feed at any time you are on this study since any drugs you are taking may also affect the child.
- •If you are capable of giving birth to or fathering a child, you must agree to use a form of birth control (examples of effective birth control are: a condom or a diaphragm with spermicidal jelly; oral, injectable, or implanted birth control; or abstinence) that is medically acceptable to your study doctor while taking part in this research study.
排除标准
- 未提供
研究组 & 干预措施
Chemotherapy
Experimental
Decitabine 20 mg/m2 IV over 1 hr days 1-5 Cytarabine 20 mg/m2 subcut days 1-5 G-CSF 5mcg/kg subcut days 1-5
干预措施: chemotherapy (Drug)
结局指标
主要结局
Response Rate
时间窗: within 30 days of last treatment
Complete Response/Complete Remission: Complete remission (CR) is defined as the presence of all of the following: * Peripheral blood - No leukemic blasts present. * No extramedullary findings of leukemia or disappearance of such (i.e. CNS or soft tissue involvement) * Bone marrow * No Auer rods * Less than 5% blast cells. * CBC and bone marrow criteria must be met within one week of each other. * Hemoglobin 9g/dl or greater * Neutrophil count \>1000 and platelet count \>100,000. * RBC Transfusion free for 2 weeks.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
终止
1 期
Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETsGliomasMedulloblastomaNeuroectodermal Tumors, PrimitiveNCT02332889University of Louisville1
招募中
2 期
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage MesotheliomaMalignant Mesothelioma (MM)Early-stage MesotheliomaSubclinical MesotheliomaBRCA1-Associated Protein-1 (BAP1) MutationsEarly-stage BAP1-associated MalignanciesMesotheliomaNCT05960773National Cancer Institute (NCI)15
招募中
2 期
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative NeoplasmsMyelodysplastic SyndromePolycythemia VeraPrimary MyelofibrosisEssential ThrombocythemiaAcute Myeloid LeukemiaSecondary MyelofibrosisNCT04282187University of Washington25
已完成
2 期
Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)Acute Myeloid LeukemiaNCT01829503Annie Im, M.D.44
招募中
2 期
A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess BlastsMyelodysplastic SyndromesMyeloproliferative Chronic Myelomonocytic LeukemiaNCT05365035M.D. Anderson Cancer Center60